IL146805A0 - Novel epidermal growth factor receptor-binding compounds for positron emission tomography - Google Patents
Novel epidermal growth factor receptor-binding compounds for positron emission tomographyInfo
- Publication number
- IL146805A0 IL146805A0 IL14680500A IL14680500A IL146805A0 IL 146805 A0 IL146805 A0 IL 146805A0 IL 14680500 A IL14680500 A IL 14680500A IL 14680500 A IL14680500 A IL 14680500A IL 146805 A0 IL146805 A0 IL 146805A0
- Authority
- IL
- Israel
- Prior art keywords
- growth factor
- factor receptor
- epidermal growth
- positron emission
- emission tomography
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/322,979 US6126917A (en) | 1999-06-01 | 1999-06-01 | Epidermal growth factor receptor binding compounds for positron emission tomography |
PCT/US2000/013749 WO2000072849A1 (en) | 1999-06-01 | 2000-05-19 | Novel epidermal growth factor receptor-binding compounds for positron emission tomography |
Publications (1)
Publication Number | Publication Date |
---|---|
IL146805A0 true IL146805A0 (en) | 2002-07-25 |
Family
ID=23257276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14680500A IL146805A0 (en) | 1999-06-01 | 2000-05-19 | Novel epidermal growth factor receptor-binding compounds for positron emission tomography |
Country Status (7)
Country | Link |
---|---|
US (1) | US6126917A (bg) |
EP (1) | EP1180034A4 (bg) |
JP (1) | JP2003500450A (bg) |
AU (1) | AU4857400A (bg) |
CA (1) | CA2375826A1 (bg) |
IL (1) | IL146805A0 (bg) |
WO (1) | WO2000072849A1 (bg) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508343A (ja) * | 2000-09-07 | 2004-03-18 | ウイスコンシン アラムニ リサーチ ファンデーション | 17f標識フルオロアルカンの合成 |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
AU2002311601C1 (en) * | 2001-06-14 | 2008-07-03 | Hadasit Medical Research Services And Development Ltd | Non-myeloablative tolerogenic treatment with tyrphostins |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
CA2491191C (en) * | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
EP1594504A4 (en) * | 2003-01-23 | 2008-12-17 | T K Signal Ltd | NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
EP1660479A1 (en) * | 2003-07-29 | 2006-05-31 | Astrazeneca AB | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
JP2007505878A (ja) * | 2003-09-19 | 2007-03-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
PL1667992T3 (pl) * | 2003-09-19 | 2007-05-31 | Astrazeneca Ab | Pochodne chinazoliny |
WO2005030757A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Quinazoline derivatives |
DK2210607T3 (da) | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
NO20035681D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
UY29398A1 (es) * | 2005-02-26 | 2006-10-02 | Astrazeneca Ab | Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións. |
EP1957468A2 (en) * | 2005-09-06 | 2008-08-20 | T.K. Signal Ltd. | Polyalkylene glycol derivatives of 4 - (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase |
JP4945133B2 (ja) * | 2006-01-19 | 2012-06-06 | 富士フイルムRiファーマ株式会社 | 4−フェノキシキナゾリン誘導体放射性化合物 |
EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
KR20090116782A (ko) * | 2007-02-06 | 2009-11-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법 |
FR2926079B1 (fr) | 2008-01-03 | 2012-12-28 | Commissariat Energie Atomique | Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations |
DK2245026T3 (da) | 2008-02-07 | 2012-10-15 | Boehringer Ingelheim Int | Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling |
ES2444128T3 (es) * | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
CA2733153C (en) * | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
NZ618004A (en) | 2009-01-16 | 2015-06-26 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US8753605B2 (en) | 2010-08-31 | 2014-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging probes, methods of making imaging probes, and methods of imaging |
CN103254140B (zh) * | 2012-02-17 | 2016-02-17 | 北京师范大学 | 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用 |
US10710968B2 (en) | 2016-01-13 | 2020-07-14 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57144266A (en) * | 1981-03-04 | 1982-09-06 | Sankyo Co Ltd | 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
NZ330868A (en) * | 1996-02-13 | 2000-01-28 | Zeneca Ltd | 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors |
WO1998010767A2 (en) * | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
WO1999061428A1 (en) * | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
US6172071B1 (en) * | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
IL141434A0 (en) * | 1998-08-21 | 2002-03-10 | Parker Hughes Inst | Quinazoline derivatives |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
JP2002539262A (ja) * | 1999-03-19 | 2002-11-19 | パーカー ヒューズ インスティテュート | キナゾリン化合物製剤および治療におけるその使用 |
-
1999
- 1999-06-01 US US09/322,979 patent/US6126917A/en not_active Expired - Lifetime
-
2000
- 2000-05-19 EP EP00930818A patent/EP1180034A4/en not_active Withdrawn
- 2000-05-19 AU AU48574/00A patent/AU4857400A/en not_active Abandoned
- 2000-05-19 CA CA002375826A patent/CA2375826A1/en not_active Abandoned
- 2000-05-19 IL IL14680500A patent/IL146805A0/xx unknown
- 2000-05-19 WO PCT/US2000/013749 patent/WO2000072849A1/en active Application Filing
- 2000-05-19 JP JP2000620961A patent/JP2003500450A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6126917A (en) | 2000-10-03 |
EP1180034A1 (en) | 2002-02-20 |
CA2375826A1 (en) | 2000-12-07 |
WO2000072849A1 (en) | 2000-12-07 |
JP2003500450A (ja) | 2003-01-07 |
AU4857400A (en) | 2000-12-18 |
EP1180034A4 (en) | 2003-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL146805A0 (en) | Novel epidermal growth factor receptor-binding compounds for positron emission tomography | |
IL150694A0 (en) | Data acquisition for computed tomography | |
PL352911A1 (en) | New compounds | |
AU3889500A (en) | Radiographic reference marker | |
AU4462800A (en) | Single photon emission computed tomography system | |
NZ513941A (en) | Permeability-modulated carrier referencing | |
PL351486A1 (en) | Prrsv vaccines | |
IL146210A0 (en) | Pyrimidinone compounds | |
GB9927555D0 (en) | X-ray fluorescence apparatus | |
HK1042303A1 (zh) | 新的化合物 | |
AU2001228845A1 (en) | Positron emission tomograph | |
HUP0500037A3 (en) | Process for preparing insulin compounds | |
EP1140083A4 (en) | NEW CONNECTIONS | |
GB9912446D0 (en) | Injectable anesthetic formulation | |
HK1042493A1 (zh) | 新的化合物 | |
EG24063A (en) | Novel compounds | |
AU2002225998A1 (en) | Data acquisition for computed tomography | |
GB2360518B (en) | Dimeric compounds | |
GB9901256D0 (en) | Novel compounds | |
GB0022691D0 (en) | Chiral polymerizable compounds | |
HUP9904624D0 (en) | New compounds | |
GB0019147D0 (en) | Computed tomography | |
GB9923169D0 (en) | Patient carrier | |
SI1202994T1 (en) | New compounds | |
AU6437100A (en) | Method for preparing optionally substituted dichloroaromatic compounds |